Mycophenolate mofetil for the treatment of systemic lupus erythematosus: An open pilot trial

Lupus

Volumn 8, Issue 9, 1999, Pages 731-736

  Gaubitz, Markus ^a   Schorat, Annette ^a   Schotte, Heiko ^a   Kern, Peter ^b   Domschke, Wolfram ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Immunosuppression; Mycophenolate mofetil treatment; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURIGO; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTIGO;

EID: 0032704059     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678840927     Document Type: Article

References (32)

1. Veda Y, Sakane T, Tsunematsu T. Hyperreactivity of activated B cells to B cell growth factor in patients with systemic lupus erythematosus. J Immunol 1989; 143: 3988-3993.
2. Klippel JH. Systemic lupus erythematosus - Management. In: JH Klippel, PA Dieppe (ed). Rheumatology. Mosby: London, 1994, pp 6.6.1-6.6.8.
3. Kimberly RP. Treatment. Corticosteroids and antiinflammatory drugs. Rheum Dis Clin North Am 1988; 14: 203-221.
4. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
5. Klippel JH. Is aggressive therapy effective for lupus? Rheum Dis Clin North Am 1993; 19: 249-261.
6. Boumpas DT, Austin HA, Vaughn EM et al. Severe lupus nephritis: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-744.
7. Swaak AJ, Statius van Eps LW, Aarden LA, Feltkamp TE. Azathioprine in the treatment of systemic lupus erythematosus. A three year prospective study. Clin Rheumatol 1984; 3: 285-291.
8. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311: 1528-1533.
9. Wilson K, Abeles M. A 2-year, open-ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 1674-1677.
10. Tokuda M, Kurata N, Mizoguchi A et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus. Arthritis Rheum 1994; 37: 551-558.
11. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolae mofetil (MMF). Clin Transplant 1996; 10: 77-84.
12. Suzuki S, Takaku S, Mori T. Antitumor activity of derivatives of mycphenolic acid. J Antibiot 1976; 29: 275-285.
13. Jones EL, Epinette WW, Hackney VC et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975; 65: 537-542.
14. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28.
15. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients. Transplantation 1997; 63: 39-47.
16. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-515.
17. Schiff MH, Goldblum R, Rees MMC. 2-Morpholino-ethyl mycophenolic acid (ME-MPA) in the treatment of refractory rheumatoid arthritis (RA). Arthritis Rheum 1990; 33(9 Suppl): s155.
18. Nowack R, Birck R, Van der Woude FJ. Mycophenolic mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774.
19. McMurray RW, Elbourne KB, Lal S. Mycophenolate mofetil prevents lupus nephritis and mortality in the female B/W mouse model of SLE. Arthritis Rheum 1997; 40(9 Suppl): S324.
20. Dooley MA, Nachman PH, Satterly KK et al. Mycophenolate mofetil in resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN) following cyclophosphamide (CyP) Therapy. Arthritis Rheum 1997; 40(9 Suppl): S58.
21. Schorat A, Schotte H, Seidel M et al. Mycophenolate mofetil: First experiences in SLE. Lupus 1998; 7(Suppl 1): 115.
22. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
23. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J Am Soc Nephrol 1999; 10: 833-839.
24. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11: 117-119.
25. Haufs MG, Beissert S, Grabbe S et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138: 179-181.
26. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997; 350: 494.
27. Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet 1997; 350: 1003.
28. Neurath MF, Duchmann R, Peters M et al. Mycophenolate mofetil/cortison versus azathioprine/cortison for treatment of active inflammatory bowel disease: Preliminary results of a prospective randomised study. Endoscopy 1997; 7: P822.
29. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997; 56: 382-385.
30. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol 1998; 25: 243-246.
31. Dostal C, Tesar V, Rychlik I et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998; 7: 29-36.
32. Callen JP, Spencer LV, Burruss JB et al. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leucocytoclastic vasculitis. Arch Dermatol 1991; 127: 515-522.